Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients:
All studies: RR 0.66 [95%CI 0.53, 0.83], p
< 0.001; I2: 42%
RCTs: RR 0.81 [95%CI 0.54, 1.20], p
= 0.29; I2: 10%
The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.
Currently there are 40 colchicine studies
and meta analysis shows:
Zein et al., 12 Jan 2022, peer-reviewed, 2 authors.